Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 51 results for copd exacerbation

  1. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

    This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.

  2. Asthma (QS25)

    This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.

  3. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  4. Digital supported self-management technologies for adults with chronic obstructive pulmonary disease: early value assessment

    In development [GID-HTE10030] Expected publication date: 15 August 2024

  5. Virtual Wards for COPD exacerbations

    Awaiting development [GID-MT608] Expected publication date: TBC

  6. Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) (QS210)

    This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.

  7. Prophylactic antibiotics for preventing exacerbations:- Which subgroups of people with stable COPD who are at high risk of exacerbations are most likely to benefit from prophylactic antibiotics?

    antibiotics for preventing exacerbations:- Which subgroups of people with stable COPD who are at high risk of...

  8. COPD: annual review

    This indicator covers the percentage of patients with COPD on the register, who have had a review in the preceding 12 months, including a record of the number of exacerbations and an assessment of breathlessness using the Medical Research Council dyspnoea scale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM170

  9. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different antibiotics, doses and regimens of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    NG115/8 Question Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of different antibiotics,...

  10. Prophylactic antibiotics for preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    preventing exacerbations:- What is the comparative effectiveness of seasonal versus continuous prophylactic antibiotics for people with...

  11. Prophylactic antibiotics for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic antibiotics for people with stable COPD who are at high risk of exacerbations?

    for preventing exacerbations: - What is the long-term clinical and cost effectiveness of prophylactic antibiotics for people with stable...

  12. Idiopathic pulmonary fibrosis in adults (QS79)

    This quality standard covers managing idiopathic pulmonary fibrosis (gradual scarring of the lungs) in adults. It includes diagnosis by a multidisciplinary team, managing symptoms and palliative care. It describes high-quality care in priority areas for improvement.

  13. Mucolytic therapy:- In people with COPD, does mucolytic drug therapy prevent exacerbations in comparison with placebo and other therapies?

    Question Mucolytic therapy:- In people with COPD, does mucolytic drug therapy prevent exacerbations in comparison with...

  14. Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)

    Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.

  15. Air pollution: outdoor air quality and health (QS181)

    This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.